及时明确的诊断对于提高弥漫性低级别胶质瘤的治疗效果及延长患者生存时间有着重要意义，但目前弥漫性低级别胶质瘤的诊疗方案仍处于探索阶段，在诊断方面仍主要依赖于影像学检查，其中又以MRI的应用最为普遍，但单一影像学检查在实际诊疗活动中的应用局限日益突出，对此，国内外正在尝试突破传统的组织学病理分型，从分子层面对弥漫性低级别胶质瘤进行病理分型，以提高诊断精准性及预后评估精确性。笔者现围绕当前弥漫性低级别胶质瘤的临床影像学及分子病理分型的相关研究进展综述如下，以期为弥漫性低级别胶质瘤的诊疗提供参考借鉴。“,”Timely and clear diagnosis is of great significance to improve the therapeutic effect of diffuse low-grade glioma (DLG) and prolong the survival time of patients. However, the current diagnosis and treatment plans of DLG are still in the exploratory stage, and the diagnosis mainly depends on imaging examination, among which, MR imaging is the most common one, but the application of single imaging diagnosis in the actual diagnosis and treatment is limited, and more and more attention has been paid to it. In order to improve the accuracy of diagnosis and prognosis evaluation, we tend to break through the traditional histopathological classification at home and abroad. We summarize the relevant research progress in clinical imaging and molecular pathology classification of DLG as follows, to provide references for diagnoses and treatments of DLG.